LivaNova (NASDAQ:LIVN) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research note published on Wednesday morning.

A number of other research analysts also recently commented on LIVN. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Mizuho lowered their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. The Goldman Sachs Group began coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. Robert W. Baird lifted their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of LivaNova in a research report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $69.17.

LivaNova Stock Performance

Shares of LivaNova stock opened at $47.63 on Wednesday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a 12 month low of $43.15 and a 12 month high of $64.47. The business has a fifty day simple moving average of $49.74 and a 200-day simple moving average of $50.20. The stock has a market cap of $2.59 billion, a PE ratio of 113.40 and a beta of 0.98.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

Several institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. Canada Pension Plan Investment Board acquired a new position in LivaNova during the second quarter valued at approximately $88,000. Central Pacific Bank Trust Division acquired a new position in LivaNova in the 3rd quarter valued at $178,000. Captrust Financial Advisors acquired a new position in LivaNova in the 3rd quarter valued at $217,000. Sanctuary Advisors LLC bought a new position in LivaNova in the 3rd quarter worth $219,000. Finally, Edgestream Partners L.P. acquired a new position in LivaNova during the 3rd quarter worth $244,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.